Provectus Biopharmaceuticals, Inc. · OTC:PVCT
Provectus Biopharmaceuticals — Shareholder Meeting (June 2021)
17 slides from Provectus Biopharmaceuticals's shareholder meeting presentation, Jun 23, 2021
Slide 1: 2021 Annual Shareholder Meeting
@® provectus biopharmaceuticals 2021 Annual Shareholder Meeting Wednesday, June 234 10025 Investment Drive, Suite 250, Knoxville, Tennessee, USA 37932 | provectusbio.com | © 2021, Provectus Biopharmaceuticals, Inc.
Slide 2: Forward-Looking Statements
Forward-Looking Statements The information in this presentation may include “forward-looking statements,” within the meaning of U.S. securities legislation, relating to the business of Provectus Biopharmaceuticals, Inc. and its affiliates (Provectus or the Company), which are based on the opinions a
Slide 3: 2021 Annual Shareholder Meeting Agenda
2021 Annual Shareholder Meeting Agenda % o Part 1: Shareholder Meeting Activities o Part 2: Company Update e Welcome/Introduction e Opening Remarks e Preliminary Matters e Building a Medical Science Platform . ; and a Broad-Spectrum Drug Product Candidate Pipeline e Order of Business/Other Business
Slide 4: Part 1: Shareholder Meeting Activities
Part 1: Shareholder Meeting Activities 4 © 2021, Provectus Biopharmaceuticals, Inc.
Slide 5: Shareholder Meeting Activities
Shareholder Meeting Activities o Welcome o Introductions o Preliminary Matters Inspector of the Election Record Date Shares Entitled to Notice and Vote Quorum Reading of the Notice of the Meeting, Affidavit of Mailing, and Minutes Stockholders’ Proxies Stockholders’ Ballots Gv o Order of Business e
Slide 6: Part 2:
Part 2: Company Update 6 © 2021, Provectus Biopharmaceuticals, Inc.
Slide 7: Opening Remarks
LY Opening Remarks Ed Pershing, CPA Chair, Board of Directors tf © 2021, Provectus Biopharmaceuticals, Inc.
Slide 8: Building a Medical Science Platform
LY Building a Medical Science Platform and a Broad-Spectrum Drug Product Candidate Pipeline Dominic Rodrigues Vice Chair, Board of Directors 2021, Provectus Biopharmaceuticals, Inc.
Slide 9: The Underpinnings of a Robust Medical Science Platform
The Underpinnings of a Robust Medical Science Platform % o We believe that a well-built platform requires versatile, consistent, and reproducible science e Recognizable, understandable, and/or novel targeting e A sound tolerability profile e Multi-mechanism behavior e Response-, curative-, and/or re
Slide 10: An Outsider's Initial View of Provectus' Science & Data: Small Molecule Immunotherapy
An Outsider’s Initial View of Provectus’ Science & Data: Small Molecule Immunotherapy % o In Provectus, pre-2017, we saw the possibilities of disruptive medical science (based on the publicly-available portfolio of company data) with far-reaching promise, vast potential, and some knowledge gaps e A
Slide 11: Validating a Science Platform vs. Pursuing a Single Disease Indication
Validating a Science Platform vs. Pursuing a Single Disease Indication % o During the time period between securing board control in 2017 and the business turnaround work into 2018, we considered: e The tenets of platform-capable medical science e Provectus’ proprietary and sponsored preclinical rese
Slide 12: Provectus Annual Shareholder Meetings: Decision-Making in Plain Sight
Provectus Annual Shareholder Meetings: Decision-Making in Plain Sight % o 2018. We communicated our new vision of health equity-driven drug development and described the Company’s inventory of clinical data e Previously, a singular focus on IL oncology and, specifically, in-transit melanoma; this ap
Slide 13: Our Strategy for 2021 and Beyond
o e Pursue commercialization of existing IL oncology programs where data support regulatory engagement (e.g., in-transit melanoma unsuitable for checkpoint blockade, refractory symptomatic neuroendocrine cancer metastatic to the liver) Our Strategy for 2021 and Beyond o Drug discovery & development
Slide 14: Option Value: Platform Expansion Beyond Oncology
Option Value: Platform Expansion Beyond Oncology % o We plan to continue nurturing opportunities that have the potential to expand Provectus’ platform beyond oncology, and advancing existing and prospective new potential monotherapy and combination therapy treatments for global patient populations u
Slide 15: 2020-2021 Medical Conference Presentations and Peer-Reviewed Journal Publications
2020-2021 Medical Conference Presentations and Peer-Reviewed Journal Publications % 1. A phase 1b study of rose bengal disodium and anti-PD-1 in metastatic cutaneous melanoma: results in patients naive to immune checkpoint blockade; September 2020, European Society for Medical Oncology (ESMO) Congre
Slide 16: Q&A
Q&A Board of Directors 16 11, Provectus Biopharmaceuticals, Inc.
Slide 17: Closing Remarks
LY Closing Remarks Bruce Horowitz Chief Operating Officer and Member, Board of Directors te © 2021, Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals — Shareholder Meeting (June 2021) on 6ix